CAJ | 학술논문

目的：研究吸烟对卡马西平治疗原发性三叉神经痛效果的影响。方法：选取原发性三叉神经痛患者203例,根据有无吸烟史分为吸烟组、非吸烟组。所有患者采用相同的治疗方案：卡马西平0.1g,2次/d口服,逐渐加量至疼痛完全消失,后逐渐减量至最小维持剂量。记录每个患者最小维持剂量,算出最小维持剂量/体表面积(S值,g/m2)。对所有患者进行规律电话随访,电话随访时间1次/3月。再次加量或者放弃服药选择其他治疗视为治疗失败。记录最小维持剂量应用后的无进展时间(PFS)。比较各组治疗成功率、S值以及PFS。结果：吸烟组92人,非吸烟组111人。吸烟组中成功率58.7%,非吸烟组中成功率79.3%(χ2=10.14,P=0.001<0.05)；吸烟组中S值为(0.61±0.24)g/m2,非吸烟组中S值为(0.30±0.16)g/m2,(F=121.46,P<0.001)；两组PFS比较,结果提示吸烟组PFS为(37.09±2.31)个月,非吸烟组为(58.73±1.43)个月(χ2=35.38,P<0.001)。结论：吸烟可降低卡马西平治疗原发性三叉神经痛的成功率,增加最小维持剂量和缩短无进展生存时间。戒烟是否能够提高卡马西平治疗原发性三叉神经痛效果需要进一步研究。
목적：연구흡연대잡마서평치료원발성삼차신경통효과적영향。방법：선취원발성삼차신경통환자203례,근거유무흡연사분위흡연조、비흡연조。소유환자채용상동적치료방안：잡마서평0.1g,2차/d구복,축점가량지동통완전소실,후축점감량지최소유지제량。기록매개환자최소유지제량,산출최소유지제량/체표면적(S치,g/m2)。대소유환자진행규률전화수방,전화수방시간1차/3월。재차가량혹자방기복약선택기타치료시위치료실패。기록최소유지제량응용후적무진전시간(PFS)。비교각조치료성공솔、S치이급PFS。결과：흡연조92인,비흡연조111인。흡연조중성공솔58.7%,비흡연조중성공솔79.3%(χ2=10.14,P=0.001<0.05)；흡연조중S치위(0.61±0.24)g/m2,비흡연조중S치위(0.30±0.16)g/m2,(F=121.46,P<0.001)；량조PFS비교,결과제시흡연조PFS위(37.09±2.31)개월,비흡연조위(58.73±1.43)개월(χ2=35.38,P<0.001)。결론：흡연가강저잡마서평치료원발성삼차신경통적성공솔,증가최소유지제량화축단무진전생존시간。계연시부능구제고잡마서평치료원발성삼차신경통효과수요진일보연구。
Objective:To study whether smoking affects the effect of carbamazepine for primary trigeminal neuralgia.Methods:203 patients from September 2005 to September 2013 with complaint primary trigeminal neuralgia was involved in this study.Smoking group and non-smoking group was assessed according to smoking history.All of the patients were applied for the same treatment:carbamazepine 0.1g,twice a day,orally,and the amount was added gradually for complete resolution of pain,then reduced to the minimum maintenance dose.Minimum maintenance dose was recorded for each patient,and a Svalue (g/m2 )was calculated by minimum maintenance dose/body surface area.All patients was followed up by telephone every three months.Record the minimum ma-intenance dose after application of progression-free time (PFS).Increased does or choose other therapies as a treatment was considered failure.Successful rate,S value and PFS between the two group was compared.Results:There are 92 patients in smoking group and 111 in non-smoking group.Successful rate in smoking group was 58.7% and 79.3% in non-smoking group success (χ2=10.14,P=0.001<0.05);S value in smoking group was(0.61±0.24)g/m2 while(0.30±0.16)g/m2 in non-smoking group(F=121.46,P<0.001);PFS was(37.09±2.31)months in smoking group and(58.73±1.43)months in non-smoking group(χ2 =35.38,P <0.001). Conclusion:Smoking decreases successful rate,increases minimum maintenance dose and shortens progression-free survival time in car-bamazepine treatment for primary trigeminal neuralgia.Whether quitting smoking can improve the effect of carbamazepine for primary trigeminal neuralgia needs further research.